Learning Portfolio: Eli Lilly – Diabetes Treatment Update – Diabetes – Insulin and GLP 1
Topic: Diabetes Treatment Update – Diabetes – Insulin and GLP 1
Points to be discussed
- Reviews the physiology of GLP-1 and outlines the benefits and evolution of the GLP-1 receptor agonist class, for treatment of Type 2 Diabetes patients.
- Introduces the once-weekly GLP-1 receptor agonist dulaglutide, and provides an overview of its efficacy and safety clinical data from the AWARD trial program
- Reviews the evolution of cardiovascular outcomes trials for GLP1-RAs and outlines the primary prevention demonstrated by dulaglutide in the REWIND study.
Speaker: Dr Emmanuel Danso
Date: 28 June 2022
Time 13h30 – 14h30